Amit Sharma, MD
Interventional Cardiology · Merritt Island, FLNPI 1730396706
Payments from drug & device makers
Across 400 payments — averaging $851.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$308K
- Novartis$23K
- Abbott$2K
- Penumbra, Inc.$2K
- Boston Scientific$2K
- AstraZeneca$1K
- plus $3K from 27 others
What the payments were for
- Consulting fees$2,9701%
- Speaking & faculty fees$279,71082%
- Travel & lodging$47,59114%
- Food & beverage$10,0903%
- Education$1630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 253 | $308,174 |
| Novartis | 33 | $22,625 |
| Abbott | 6 | $2,189 |
| Penumbra, Inc. | 4 | $1,890 |
| Boston Scientific | 11 | $1,645 |
| AstraZeneca | 4 | $1,070 |
| Abiomed | 11 | $671 |
| Medtronic | 7 | $265 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $197 |
| Shockwave Medical, Inc | 2 | $185 |
| Biosense Webster, Inc. | 3 | $182 |
| E.r. Squibb & Sons, L.L.C. | 11 | $176 |
| Amarin Pharma, Inc. | 3 | $158 |
| Baylis Medical Company Inc | 1 | $149 |
| Amgen | 7 | $121 |
| Edwards Lifesciences | 3 | $108 |
| Boehringer Ingelheim | 5 | $98 |
| Pfizer | 5 | $84 |
| Cvrx, Inc. | 3 | $79 |
| Vital Connect, Inc | 2 | $67 |
| Impulse Dynamics (USA) Inc. | 1 | $65 |
| Kerecis Limited | 1 | $62 |
| Esperion Therapeutics, Inc. | 3 | $46 |
| Novo Nordisk | 2 | $34 |
| Astellas Pharma US Inc | 2 | $30 |
| Lexicon Pharmaceuticals, Inc. | 2 | $30 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $25 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $24 |
| Bayer | 1 | $23 |
| Kestra Medical Technology Services, Inc. | 1 | $19 |
| Biotronik Inc. | 1 | $14 |
| MML US, Inc. | 1 | $14 |
| Cardiovascular Systems Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$305,092
- ENTRESTO$22,140
- AMPLATZER AMULET$2,076
- Indigo System$1,884
- Watchman$1,124
- Impella$312
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$169
- NRG needle$149
- ACCOLADE SR$147
- AVVIGO Guidance System$138
- Vascepa$125
- General - Balloon Catheters$111
- FARXIGA$108
How this compares
$340,524 in reported general payments places this provider in the 90th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 375 | $421,698 |
| EntrestoSacubitril/Valsartan | 228 | $314,451 |
| XareltoRivaroxaban | 291 | $289,979 |
| Repatha SureclickEvolocumab | 92 | $99,669 |
| FarxigaDapagliflozin Propanediol | 67 | $85,368 |
| Repatha SyringeEvolocumab | 46 | $46,128 |
| JardianceEmpagliflozin | 28 | $35,653 |
| InpefaSotagliflozin | 16 | $16,600 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 41 | $13,479 |
| VascepaIcosapent Ethyl | 12 | $12,153 |
| Ranolazine ErRanolazine | 72 | $11,592 |
| Rosuvastatin Calcium | 720 | $10,997 |
| Metoprolol Succinate | 537 | $7,250 |
| Praluent PenAlirocumab | 11 | $7,108 |
| Carvedilol | 558 | $4,487 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $84 | $421,698375 claims |
| NovartisEntresto | $22,625 | $314,451228 claims |
| Johnson & JohnsonXarelto | $308,174 | $289,979291 claims |
| AstraZenecaFarxiga | $1,070 | $85,36867 claims |
| Boehringer IngelheimJardiance | $98 | $35,65328 claims |
| Lexicon Pharmaceuticals, Inc.Inpefa | $30 | $16,60016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Merritt Island
- Dominick AngiolilloJacksonville$4M
- Douglas SpriggsClearwater$3.2M
- Rakesh PrashadOcala$3.1M
- Aldo Martinez FleitesMiami Lakes$2.2M
- Rohit AminPensacola$2M
- Roberto CubedduNaples$2M
- Arthur LeeGainesville$2M
- Ruby SatpathyJacksonville$1.8M
- Santhosh MathewsBradenton$1.7M
- Pedro Martinez-ClarkMiami$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.